<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02738450</url>
  </required_header>
  <id_info>
    <org_study_id>ACI-24-1301</org_study_id>
    <secondary_id>1R01AG047922-01</secondary_id>
    <nct_id>NCT02738450</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome</brief_title>
  <acronym>3-Star</acronym>
  <official_title>A Phase Ib Multi-Center, Double-Blind, Randomized, Placebo-Controlled Dose Escalation Study of the Safety, Tolerability and Immunogenicity of ACI-24 in Adults With Down Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AC Immune SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alzheimer's Disease Cooperative Study (ADCS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LuMind IDSC Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AC Immune SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test in adults with Down Syndrome the safety, tolerability&#xD;
      and immunogenicity of a vaccine, ACI-24.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective multi-center, placebo controlled, double-blind and randomized dose&#xD;
      escalation study of 2 doses of ACI-24 versus Placebo over 24 months with a total of 21&#xD;
      visits.&#xD;
&#xD;
      All subjects will receive the study medication (ACI-24 or Placebo) 7 times via s.c. injection&#xD;
      (12 months) and will be followed up for 12 months after the last dose with a final safety and&#xD;
      efficacy assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">June 2020</completion_date>
  <primary_completion_date type="Actual">June 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody Titer (Serum Anti-Aβ1-42 Free IgG) - Mean Absolute Value</measure>
    <time_frame>Values at baseline (week 0) and week 50 are reported</time_frame>
    <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
The measure is expressed in Arbitrary Units per mL (AU/mL). AU/mL in a sample is obtained by back-calculation towards the standard curve.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amyloid Beta 1-40 in Blood - Mean Absolute Value</measure>
    <time_frame>Values at baseline (week 0) and week 50 are reported</time_frame>
    <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CANTAB - MOT Latency Score</measure>
    <time_frame>Values at baseline (week 0) and week 50 are reported</time_frame>
    <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Cambridge Neuropsychological Test Automated Battery (CANTAB), Motor Screening Task (MOT) is a cognitive scale to be completed by the subject.&#xD;
Range score from 0 to ∞, lower score means a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CANTAB - PAL First Attempt Memory Score</measure>
    <time_frame>Values at baseline (week 0) and week 50 are reported</time_frame>
    <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Cambridge Neuropsychological Test Automated Battery (CANTAB), Paired Associate Learning (PAL) is a cognitive scale to be completed by the subject.&#xD;
Range score from 0 to 20, higher score means a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Praxis Test (BPT) - Total Score</measure>
    <time_frame>Values at baseline (week 0) and week 50 are reported</time_frame>
    <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Brief Praxis Test (BPT) is a cognitive scale to be completed by the subject.&#xD;
Range score from 0 to 80, higher score means better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vineland II - Communication Domain Standard Score</measure>
    <time_frame>Values at baseline (week 0) and week 50 are reported</time_frame>
    <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Vineland II is a behavioral questionnaire to be completed by the study partner of the subject.&#xD;
Range score from 0 to 113, higher score means a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vineland II - Daily Living Skill - Domain Standard Score</measure>
    <time_frame>Values at baseline (week 0) and week 50 are reported</time_frame>
    <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Vineland II is a behavioral questionnaire to be completed by the study partner of the subject.&#xD;
Range score from 0 to 114, higher score means a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vineland II - Socialisation - Domain Standard Score</measure>
    <time_frame>Values at baseline (week 0) and week 50 are reported</time_frame>
    <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Vineland II is a behavioral questionnaire to be completed by the study partner of the subject.&#xD;
Range score from 0 to 115, higher score means a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NPI - Total Score</measure>
    <time_frame>Values at baseline (week 0) and week 50 are reported.</time_frame>
    <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Neuropsychiatric Inventory (NPI) is a behavioral questionnaire to be completed by the study partner of the subject.&#xD;
Range score from 0 to 144, higher score means a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change (CGIC) - Change From Baseline at Week 50</measure>
    <time_frame>Values at baseline (week 0) and week 50 are reported</time_frame>
    <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Clinical Global Impression of Change (CGIC) is a global assessment to be completed by the investigator.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Down Syndrome</condition>
  <arm_group>
    <arm_group_label>ACI-24 low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaccine formulation will be administrated s.c. 7 times.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACI-24 high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaccine formulation will be administrated s.c. 7 times.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo is ready-to-use solution for injection, administrated s.c. 7 times.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACI-24 low dose</intervention_name>
    <description>ACI-24 administered as a sterile suspension in PBS via s.c. injection.</description>
    <arm_group_label>ACI-24 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACI-24 high dose</intervention_name>
    <description>ACI-24 administered as a sterile suspension in PBS via s.c. injection.</description>
    <arm_group_label>ACI-24 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is a standard PBS sterile solution administrated via s.c. injection.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PBS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females with Down Syndrome aged ≥25 to ≤45 years, with a cytogenetic&#xD;
             diagnosis being either Trisomy 21 or Complete Unbalanced Translocation of the&#xD;
             Chromosome 21.&#xD;
&#xD;
          -  Subjects and their study partner/legal representative in the opinion of the&#xD;
             investigator able to understand and to provide written informed consent.&#xD;
&#xD;
          -  Written informed consent obtained from subjects and their study partner/legal&#xD;
             representative before any trial-related activities.&#xD;
&#xD;
          -  In the opinion of the investigator able to fully participate in the trial and&#xD;
             sufficiently proficient in English to be capable of reliably completing study&#xD;
             assessments.&#xD;
&#xD;
          -  Subjects have a study partner/legal representative who have direct contact with the&#xD;
             subjects at least 10 hours per week and who can be asked questions about the subjects.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects weighing less than 40 kg.&#xD;
&#xD;
          -  IQ less than 40 (as assessed by Kaufman Brief Intelligence Test, Second Edition&#xD;
             (KBIT-2).&#xD;
&#xD;
          -  In the investigators opinion, any clinically significant current psychiatric or&#xD;
             neurologic illness, including a past illness with a risk of recurrence, other than&#xD;
             Down syndrome.&#xD;
&#xD;
          -  Any medical condition likely to significantly hamper the evaluation of safety of the&#xD;
             study drug.&#xD;
&#xD;
          -  DSM-IV criteria for drug or alcohol abuse or dependence currently met within the past&#xD;
             five years.&#xD;
&#xD;
          -  History or presence of uncontrolled seizures. If history of seizures, they must be&#xD;
             well controlled with no occurrence of seizures in the past 2 years prior to study&#xD;
             screening. The use of anti-epileptic medications is permitted.&#xD;
&#xD;
          -  History of meningitis or meningoencephalitis.&#xD;
&#xD;
          -  History of malignant neoplasms within 3 years prior to study screening or where there&#xD;
             is current evidence of recurrent or metastatic disease.&#xD;
&#xD;
          -  History of persistent cognitive deficits immediately following head trauma.&#xD;
&#xD;
          -  History of inflammatory neurology disorders.&#xD;
&#xD;
          -  History of autoimmune disease with potential for CNS involvement.&#xD;
&#xD;
          -  MRI scan at screening showing a single area of cerebral vasogenic edema, superficial&#xD;
             siderosis, or evidence of a prior macrohemorrhage, or showing more than four cerebral&#xD;
             microhemorrhages (regardless of their anatomical location or diagnostic&#xD;
             characterization as &quot;possible&quot; or &quot;definite&quot;).&#xD;
&#xD;
          -  MRI examination cannot be done for any reason, including metal implants&#xD;
             contraindicated for MRI studies and/or severe claustrophobia.&#xD;
&#xD;
          -  Significant hearing or visual impairment or other issues judged relevant by the&#xD;
             investigator preventing to comply with the protocol and to perform the outcome&#xD;
             measures.&#xD;
&#xD;
          -  Severe infections or a major surgical operation within 3 months prior to screening.&#xD;
&#xD;
          -  History of chronic or recurrent infections judged to be clinically significant by the&#xD;
             investigator.&#xD;
&#xD;
          -  History or presence of immunological or inflammatory conditions which are judged to be&#xD;
             clinically significant by the investigator.&#xD;
&#xD;
          -  Celiac disease not on a gluten free diet for at least 3 months prior to study&#xD;
             screening.&#xD;
&#xD;
          -  Chronic benign skin pathologies, unless viewed as clinically insignificant in the&#xD;
             investigator's opinion.&#xD;
&#xD;
          -  Any vaccine received within the past 2 months before baseline, except influenza&#xD;
             vaccine which if indicated must be given at least 2 weeks prior to baseline.&#xD;
&#xD;
          -  Clinically significant arrhythmias or other abnormalities on ECG at screening. (Minor&#xD;
             abnormalities documented as clinically insignificant by the investigator will be&#xD;
             allowed.)&#xD;
&#xD;
          -  Clinically significant abnormal vital signs including sustained sitting blood pressure&#xD;
             greater than 160/90 mmHg.&#xD;
&#xD;
          -  In the opinion of the site investigator, deviations from normal values for hematologic&#xD;
             parameters, liver function tests, and other biochemical measures, that are judged to&#xD;
             be clinically significant.&#xD;
&#xD;
          -  Subjects with treated hypothyroidism not on a stable dose of medication for at least 3&#xD;
             months prior to screening and having clinically significant abnormal serum T-4 and TSH&#xD;
             at screening.&#xD;
&#xD;
          -  Subjects with diabetes mellitus with an HbA1c of ≥ 8.0%.&#xD;
&#xD;
          -  Subjects who have been receiving any experimental drug for Down Syndrome with a&#xD;
             washout less than 30 days or less than five halflives of the drug, whichever is&#xD;
             longer.&#xD;
&#xD;
          -  Female subjects being pregnant as confirmed by serum testing at screening or planning&#xD;
             to be pregnant or lactating.&#xD;
&#xD;
          -  Female subjects not using a reliable method of contraception (unless abstaining).&#xD;
&#xD;
          -  Patient receiving any anticoagulant drug, or aspirin at doses greater than 100 mg&#xD;
             daily in the 7 days prior to lumbar puncture (in order to avoid risk of bleeding&#xD;
             during scheduled or unscheduled lumbar puncture)&#xD;
&#xD;
          -  Use of antidepressants other than SSRI/SNRIs at stable dose, antipsychotics (typical&#xD;
             or atypical), GABA agonists (e.g. gabapentin), or stimulants (e.g. methylphenidate,&#xD;
             modafinil). In exceptional cases, low doses of atypical antipsychotics (e.g.&#xD;
             risperidone up to 0.5 mg/day or quetiapine up to 50 mg/day) or benzodiazepines are&#xD;
             only allowed after review by the site principal investigator, in consultation with the&#xD;
             project director and/or medical monitors.&#xD;
&#xD;
          -  Current use of immunosuppressant or immunomodulating drugs or their use within the&#xD;
             past 6 months prior to study screening. Current use of steroids or their use within&#xD;
             the past 3 months prior to study screening.&#xD;
&#xD;
          -  Use of Cholinesterase Inhibitor or use of Glutamatergic drugs (Topiramate, Memantine,&#xD;
             Lamotrigine) if not on stable dose for at least 3 months prior to screening.&#xD;
&#xD;
          -  Subjects who have donated blood or blood products during the 30 days prior to&#xD;
             screening who plan to donate blood while participating in the study or within four&#xD;
             weeks after completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael S. Rafii, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>USC Keck School of Medicine of the University of Southern California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Adult Down Syndrome Program</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-1712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 1, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <results_first_submitted>July 6, 2021</results_first_submitted>
  <results_first_submitted_qc>August 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 21, 2021</results_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cognitive decline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Down Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to de-identified, individual and trial -level data (analysis datasets), and other information (e.g., protocols) will be provided.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_access_criteria>These clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research and will be provided after review and approval of their research proposal, their Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). Data sharing shall be in accordance with ADCS' data sharing plan in its grant application and applicable NIH policy in effect at the time of the NIH award.</ipd_access_criteria>
    <ipd_url>https://www.adcs.org/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 28, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT02738450/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT02738450/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Twenty subjects were screened (signed the informed consent) but four participants were considered screen failures</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ACI-24 300µg</title>
          <description>Cohort 1: Low dose</description>
        </group>
        <group group_id="P2">
          <title>ACI-24 1000µg</title>
          <description>Cohort 2: High dose</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo cohort 1 + cohort 2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The data of the 20 subjects who have signed the informed consent (ie including the screen failure subject) have been considered.</population>
      <group_list>
        <group group_id="B1">
          <title>ACI-24 300µg</title>
          <description>Cohort 1: Low dose</description>
        </group>
        <group group_id="B2">
          <title>ACI-24 1000µg</title>
          <description>Cohort 2: High dose</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo cohort 1 + cohort 2</description>
        </group>
        <group group_id="B4">
          <title>Screen Failure</title>
          <description>Screen failure cohort 1 + cohort 2</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" spread="4.6"/>
                    <measurement group_id="B2" value="31.5" spread="4.9"/>
                    <measurement group_id="B3" value="33.0" spread="4.2"/>
                    <measurement group_id="B4" value="34.0" spread="2.6"/>
                    <measurement group_id="B5" value="32.9" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.0" spread="9.9"/>
                    <measurement group_id="B2" value="39.9" spread="9.4"/>
                    <measurement group_id="B3" value="43.1" spread="12.7"/>
                    <measurement group_id="B4" value="42.8" spread="11.6"/>
                    <measurement group_id="B5" value="40.2" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>KBIT 2: IQ Composite</title>
          <description>The 20 subjects who have signed the informed consent (ie including the 4 screen failure subjects) have completed the KBIT 2.&#xD;
The KBIT 2 range score is from 40 to 160, lower score means a worse outcome</description>
          <units>IQ score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.2" spread="5.5"/>
                    <measurement group_id="B2" value="49.2" spread="9.5"/>
                    <measurement group_id="B3" value="46.0" spread="8.0"/>
                    <measurement group_id="B4" value="52.8" spread="18.9"/>
                    <measurement group_id="B5" value="47.8" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Antibody Titer (Serum Anti-Aβ1-42 Free IgG) - Mean Absolute Value</title>
        <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
The measure is expressed in Arbitrary Units per mL (AU/mL). AU/mL in a sample is obtained by back-calculation towards the standard curve.</description>
        <time_frame>Values at baseline (week 0) and week 50 are reported</time_frame>
        <population>Modified Intent to Treat Population (mITT)</population>
        <group_list>
          <group group_id="O1">
            <title>ACI-24 300µg</title>
            <description>Cohort 1: Low dose</description>
          </group>
          <group group_id="O2">
            <title>ACI-24 1000µg</title>
            <description>Cohort 2: High dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo cohort 1 + cohort 2</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Titer (Serum Anti-Aβ1-42 Free IgG) - Mean Absolute Value</title>
          <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
The measure is expressed in Arbitrary Units per mL (AU/mL). AU/mL in a sample is obtained by back-calculation towards the standard curve.</description>
          <population>Modified Intent to Treat Population (mITT)</population>
          <units>AU/mL (AU: Arbitrary Unit)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="632.3" spread="570.9"/>
                    <measurement group_id="O2" value="335.4" spread="157.4"/>
                    <measurement group_id="O3" value="162.8" spread="84.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="751.5" spread="825.6"/>
                    <measurement group_id="O2" value="434.3" spread="224.3"/>
                    <measurement group_id="O3" value="153.3" spread="140.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amyloid Beta 1-40 in Blood - Mean Absolute Value</title>
        <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.</description>
        <time_frame>Values at baseline (week 0) and week 50 are reported</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>ACI-24 300µg</title>
            <description>Cohort 1: Low dose</description>
          </group>
          <group group_id="O2">
            <title>ACI-24 1000µg</title>
            <description>Cohort 2: High dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo cohort 1 + cohort 2</description>
          </group>
        </group_list>
        <measure>
          <title>Amyloid Beta 1-40 in Blood - Mean Absolute Value</title>
          <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.</description>
          <population>mITT</population>
          <units>ng/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.7" spread="56.6"/>
                    <measurement group_id="O2" value="138.5" spread="41.1"/>
                    <measurement group_id="O3" value="169.5" spread="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.8" spread="18.7"/>
                    <measurement group_id="O2" value="186.2" spread="37.8"/>
                    <measurement group_id="O3" value="181.3" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CANTAB - MOT Latency Score</title>
        <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Cambridge Neuropsychological Test Automated Battery (CANTAB), Motor Screening Task (MOT) is a cognitive scale to be completed by the subject.&#xD;
Range score from 0 to ∞, lower score means a better outcome</description>
        <time_frame>Values at baseline (week 0) and week 50 are reported</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>ACI-24 300µg</title>
            <description>Cohort 1: Low dose</description>
          </group>
          <group group_id="O2">
            <title>ACI-24 1000µg</title>
            <description>Cohort 2: High dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo cohort 1 + cohort 2</description>
          </group>
        </group_list>
        <measure>
          <title>CANTAB - MOT Latency Score</title>
          <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Cambridge Neuropsychological Test Automated Battery (CANTAB), Motor Screening Task (MOT) is a cognitive scale to be completed by the subject.&#xD;
Range score from 0 to ∞, lower score means a better outcome</description>
          <population>mITT</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1784.5" spread="904.4"/>
                    <measurement group_id="O2" value="997.1" spread="271.8"/>
                    <measurement group_id="O3" value="1024.3" spread="193.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1781.2" spread="960.4"/>
                    <measurement group_id="O2" value="1046.3" spread="152.1"/>
                    <measurement group_id="O3" value="1002.1" spread="138.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CANTAB - PAL First Attempt Memory Score</title>
        <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Cambridge Neuropsychological Test Automated Battery (CANTAB), Paired Associate Learning (PAL) is a cognitive scale to be completed by the subject.&#xD;
Range score from 0 to 20, higher score means a better outcome</description>
        <time_frame>Values at baseline (week 0) and week 50 are reported</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>ACI-24 300µg</title>
            <description>Cohort 1: Low dose</description>
          </group>
          <group group_id="O2">
            <title>ACI-24 1000µg</title>
            <description>Cohort 2: High dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo cohort 1 + cohort 2</description>
          </group>
        </group_list>
        <measure>
          <title>CANTAB - PAL First Attempt Memory Score</title>
          <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Cambridge Neuropsychological Test Automated Battery (CANTAB), Paired Associate Learning (PAL) is a cognitive scale to be completed by the subject.&#xD;
Range score from 0 to 20, higher score means a better outcome</description>
          <population>mITT</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="5.1"/>
                    <measurement group_id="O2" value="9.2" spread="5.1"/>
                    <measurement group_id="O3" value="7.8" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="4.1"/>
                    <measurement group_id="O2" value="6.7" spread="4.3"/>
                    <measurement group_id="O3" value="9.8" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Praxis Test (BPT) - Total Score</title>
        <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Brief Praxis Test (BPT) is a cognitive scale to be completed by the subject.&#xD;
Range score from 0 to 80, higher score means better outcome</description>
        <time_frame>Values at baseline (week 0) and week 50 are reported</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>ACI-24 300µg</title>
            <description>Cohort 1: Low dose</description>
          </group>
          <group group_id="O2">
            <title>ACI-24 1000µg</title>
            <description>Cohort 2: High dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo cohort 1 + cohort 2</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Praxis Test (BPT) - Total Score</title>
          <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Brief Praxis Test (BPT) is a cognitive scale to be completed by the subject.&#xD;
Range score from 0 to 80, higher score means better outcome</description>
          <population>mITT</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" spread="5.8"/>
                    <measurement group_id="O2" value="73.7" spread="3.2"/>
                    <measurement group_id="O3" value="73.8" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" spread="4.8"/>
                    <measurement group_id="O2" value="77.5" spread="2.5"/>
                    <measurement group_id="O3" value="76.5" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vineland II - Communication Domain Standard Score</title>
        <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Vineland II is a behavioral questionnaire to be completed by the study partner of the subject.&#xD;
Range score from 0 to 113, higher score means a better outcome</description>
        <time_frame>Values at baseline (week 0) and week 50 are reported</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>ACI-24 300µg</title>
            <description>Cohort 1: Low dose</description>
          </group>
          <group group_id="O2">
            <title>ACI-24 1000µg</title>
            <description>Cohort 2: High dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo cohort 1 + cohort 2</description>
          </group>
        </group_list>
        <measure>
          <title>Vineland II - Communication Domain Standard Score</title>
          <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Vineland II is a behavioral questionnaire to be completed by the study partner of the subject.&#xD;
Range score from 0 to 113, higher score means a better outcome</description>
          <population>mITT</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" spread="10.2"/>
                    <measurement group_id="O2" value="59.3" spread="8.5"/>
                    <measurement group_id="O3" value="59.0" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2" spread="11.3"/>
                    <measurement group_id="O2" value="65.2" spread="9.4"/>
                    <measurement group_id="O3" value="61.0" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vineland II - Daily Living Skill - Domain Standard Score</title>
        <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Vineland II is a behavioral questionnaire to be completed by the study partner of the subject.&#xD;
Range score from 0 to 114, higher score means a better outcome</description>
        <time_frame>Values at baseline (week 0) and week 50 are reported</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>ACI-24 300µg</title>
            <description>Cohort 1: Low dose</description>
          </group>
          <group group_id="O2">
            <title>ACI-24 1000µg</title>
            <description>Cohort 2: High dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo cohort 1 + cohort 2</description>
          </group>
        </group_list>
        <measure>
          <title>Vineland II - Daily Living Skill - Domain Standard Score</title>
          <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Vineland II is a behavioral questionnaire to be completed by the study partner of the subject.&#xD;
Range score from 0 to 114, higher score means a better outcome</description>
          <population>mITT</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2" spread="9.9"/>
                    <measurement group_id="O2" value="68.3" spread="4.1"/>
                    <measurement group_id="O3" value="58.0" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.8" spread="11.4"/>
                    <measurement group_id="O2" value="72.8" spread="4.1"/>
                    <measurement group_id="O3" value="61.5" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vineland II - Socialisation - Domain Standard Score</title>
        <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Vineland II is a behavioral questionnaire to be completed by the study partner of the subject.&#xD;
Range score from 0 to 115, higher score means a better outcome</description>
        <time_frame>Values at baseline (week 0) and week 50 are reported</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>ACI-24 300µg</title>
            <description>Cohort 1: Low dose</description>
          </group>
          <group group_id="O2">
            <title>ACI-24 1000µg</title>
            <description>Cohort 2: High dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo cohort 1 + cohort 2</description>
          </group>
        </group_list>
        <measure>
          <title>Vineland II - Socialisation - Domain Standard Score</title>
          <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Vineland II is a behavioral questionnaire to be completed by the study partner of the subject.&#xD;
Range score from 0 to 115, higher score means a better outcome</description>
          <population>mITT</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3" spread="17.2"/>
                    <measurement group_id="O2" value="77.0" spread="9.1"/>
                    <measurement group_id="O3" value="59.0" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" spread="16.1"/>
                    <measurement group_id="O2" value="83.0" spread="10.4"/>
                    <measurement group_id="O3" value="70.3" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NPI - Total Score</title>
        <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Neuropsychiatric Inventory (NPI) is a behavioral questionnaire to be completed by the study partner of the subject.&#xD;
Range score from 0 to 144, higher score means a worse outcome</description>
        <time_frame>Values at baseline (week 0) and week 50 are reported.</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>ACI-24 300µg</title>
            <description>Cohort 1: Low dose</description>
          </group>
          <group group_id="O2">
            <title>ACI-24 1000µg</title>
            <description>Cohort 2: High dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo cohort 1 + cohort 2</description>
          </group>
        </group_list>
        <measure>
          <title>NPI - Total Score</title>
          <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Neuropsychiatric Inventory (NPI) is a behavioral questionnaire to be completed by the study partner of the subject.&#xD;
Range score from 0 to 144, higher score means a worse outcome</description>
          <population>mITT</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="3.6"/>
                    <measurement group_id="O2" value="0.3" spread="0.8"/>
                    <measurement group_id="O3" value="8.5" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.5"/>
                    <measurement group_id="O2" value="0.3" spread="0.8"/>
                    <measurement group_id="O3" value="4.0" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression of Change (CGIC) - Change From Baseline at Week 50</title>
        <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Clinical Global Impression of Change (CGIC) is a global assessment to be completed by the investigator.</description>
        <time_frame>Values at baseline (week 0) and week 50 are reported</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>ACI-24 300µg</title>
            <description>Cohort 1: Low dose</description>
          </group>
          <group group_id="O2">
            <title>ACI-24 1000µg</title>
            <description>Cohort 2: High dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo cohort 1 + cohort 2</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression of Change (CGIC) - Change From Baseline at Week 50</title>
          <description>All subjects who received at least 1 dose of the study treatment of either ACI-24 300 μg, ACI-24 1000 μg or placebo are considered.&#xD;
Clinical Global Impression of Change (CGIC) is a global assessment to be completed by the investigator.</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Marked improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The collection of Treatment Emergent Adverse Events (TEAEs) for an individual subject started after the first dose at baseline (Week 0) and finished at the end of the designated follow-up period at Week 96.</time_frame>
      <desc>Definition: Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research.</desc>
      <group_list>
        <group group_id="E1">
          <title>ACI-24 300µg</title>
          <description>Cohort 1: Low dose</description>
        </group>
        <group group_id="E2">
          <title>ACI-24 1000µg</title>
          <description>Cohort 2: High dose</description>
        </group>
        <group group_id="E3">
          <title>Placebo Cohort 1</title>
          <description>Cohort 1: Placebo</description>
        </group>
        <group group_id="E4">
          <title>Placebo Cohort 2</title>
          <description>Cohort 2: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="18" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" events="14" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institution may freely publish and disseminate the results of the Study. However Institution shall only make a Publication once the Study has been completed. Institution shall send Sponsor any Publication 60 days prior to submission and Sponsor may make editorial changes to the Publication. Institution shall delete information that Sponsor considers as Confidential and Institution shall delay Publication for an additional 60 days to protect the potential patentability of an invention.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study included a limited number of subjects, and, as a consequence, was not powered on cognition and clinical efficacy outcomes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Olivier Sol</name_or_title>
      <organization>AC Immune</organization>
      <phone>+41 21 345 91 21</phone>
      <email>clinicaltrials@acimmune.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

